Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Licenses Merck Rights to RNA Splicing Microarray Patent

NEW YORK (GenomeWeb News) - ExonHit Therapeutics has granted Merck a license to its RNA splicing microarray patent, ExonHit said yesterday.
 
The non-exclusive license gives rights to the patent -- US No. 6,881,571, titled “Qualitative Differential Screening” -- for research use only. The patent has claims directed to microarrays optimized to monitor RNA splicing events, the company said.
 
ExonHit does not expect to receive more than $150,000 in revenues per year under this agreement.
 
Additional details were not disclosed.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.